EGFR Mutation Detection Kit for Cancer Therapy Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer therapies face challenges in predicting therapeutic efficacy and drug responsiveness due to the time required for anticancer drugs to take effect, and the inability to accurately select appropriate treatments for patients, particularly in cases involving EGFR gene mutations.
Innovation Solution
A composition of primers and probes is developed for detecting EGFR gene mutations, enabling rapid detection and monitoring of EGFR gene mutations in cancer patients, which can be used to predict therapeutic responsiveness to EGFR inhibitors and guide treatment strategies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional cancer therapy assessment methods are used, then treatment efficacy can be evaluated, but it takes several weeks for therapeutic effects to appear making it impossible to predict efficacy in advance
Solution Approach 1:
The patent performs EGFR gene mutation detection before initiating cancer treatment to predict therapeutic efficacy in advance. By analyzing the patient's genetic profile beforehand, the system determines whether the patient will respond to EGFR inhibitor therapy, eliminating the need to wait weeks for clinical effects to manifest. This preliminary genetic assessment allows clinicians to predict treatment outcomes prior to drug administration.
2Productivity
If appropriate therapeutic agents are selected without pre-treatment assessment, then treatment can be initiated quickly, but patients may not respond to the chosen therapy leading to treatment failure
Solution Approach 1:
The patent implements preliminary EGFR mutation status assessment through genetic testing before selecting therapeutic agents. This pre-treatment evaluation determines whether patients harbor EGFR mutations that would make them responsive to EGFR inhibitors, ensuring that only appropriate patients receive these therapies. The principle of preliminary action is applied by performing diagnostic testing in advance to guide treatment selection, thereby avoiding ineffective treatments and improving overall therapeutic success rates.
Data Source
AI summary
The present invention relates to a composition for detecting an epidermal cell growth factor receptor gene mutation and to a kit comprising the composition and, more specifically, to a primer and probe set composition for detecting an epidermal cell growth factor gene mutation, and to a kit for detecting an EGFR gene mutation, comprising the composition. A method according to the present invention can not only predict and diagnose responsiveness to a therapeutic agent for the prognosis of a cancer patient, but also predict a cancer metastasis or relapse Thus, the method can be useful for the purposes of determining the need to administer an anticancer therapeutic agent and guiding the direction of future treatment, and for monitoring a cancer metastasis or relapse.